Nuclio Media is frequently asked which companies are producing actinium-225 today and where drug developers can obtain it. The first part of that question can be answered through public announcements, regulatory disclosures and reported supply agreements, but determining how much Ac-225 a customer can actually purchase remains far more difficult.
After years in which researchers depended largely on limited government inventories, a growing group of companies now says it is producing the alpha-emitting isotope for research, clinical development and future commercial radiopharmaceuticals. Those companies regularly announce production milestones, new facilities and long-term supply agreements, but most do not disclose current production totals, validated capacity, customer allocations, pricing or complete quality specifications.
The result is a market that looks increasingly well supplied in company announcements but remains difficult to compare from the outside. At least 10 corporate organizations or joint ventures have publicly reported producing, processing or routinely releasing Ac-225, but some share the same upstream material and should not be treated as fully independent sources.
This analysis is based entirely on publicly available company announcements, regulatory disclosures, government information and reported supply agreements available as of September 2026. Nuclio Media reviewed those claims but did not receive confidential production, pricing or quality data from the organizations listed.
PanTera, the joint venture between IBA and SCK CEN, operates a weekly early-supply program using existing Th-229 sources. The company says the program is already delivering high-purity, cGMP Ac-225 to drug developers while it constructs a larger photonuclear production platform based on electron accelerators and Ra-226 targets.
PanTera announced an expanded collaboration with TerraPower Isotopes and Belgium’s Institute for Radioelements in May 2026. TerraPower will provide additional starting material, while IRE is expected to host and operate another PanTera production line that the partners say will increase current cGMP capacity by more than 200%.
PanTera should therefore be classified as an active producer with limited early supply and substantial future capacity under development. Its current Th-229 program and planned photonuclear platform should not be described as though they are already producing at the same scale.
TerraPower Isotopes produces Ac-225 through the natural decay of Th-229. The company announced commercial-scale production in October 2024 and said it was conducting weekly production runs for pharmaceutical customers whose radiopharmaceuticals were already being evaluated in human clinical trials.
TerraPower is expanding its existing operation in Everett, Washington, while developing the $450 million Bellwether Laboratory in Philadelphia. The 250,000-square-foot facility is expected to begin production in 2029 and increase the company’s Ac-225 capacity substantially.
Cardinal Health is part of the same supply chain but performs a distinct commercial role. In December 2024, the company announced weekly Ac-225 production through its Center for Theranostics Advancement in Indianapolis in collaboration with TerraPower Isotopes, describing itself as the first organization to provide cGMP-compliant Ac-225 globally at commercial scale.
Cardinal expanded its production capacity again in 2026 to support growing clinical demand and belongs in the Ac-225 production ecosystem because it processes and releases cGMP material for pharmaceutical developers. Cardinal and TerraPower should not, however, be counted as two completely independent upstream sources of the isotope.
SpectronRx announced commercial-scale production of high-purity Ac-225 in 2025 using its proprietary production platform and says it supplies material for research, clinical development and radiopharmaceutical manufacturing from its Indiana operations. The company is expanding its production infrastructure at Grissom Aeroplex, where it controls 34 acres and plans to construct an additional 150,000-square-foot facility, but it has not released enough current output, pricing or uncommitted-capacity information to support a direct comparison with other suppliers.
Niowave produces Ac-225 using superconducting electron linear accelerators and integrated radiochemistry operations in Lansing, Michigan. Its production route begins with Th-232, creating Ac-225 through intermediate isotopes that must subsequently be separated and purified.
The company supplies Ac-225 to radiopharmaceutical developers and entered a long-term supply agreement with Novartis in February 2026. That agreement provides evidence of a commercial supply operation, but Niowave has not publicly disclosed enough current production or allocation data to determine how much capacity remains available outside its contracted customers.
IONETIX produces Ac-225 by irradiating Ra-226 targets with a proton cyclotron at its Lansing-area facility. The company announced its first production batch in June 2024 and has since entered supply relationships supporting clinical and commercial radiopharmaceutical programs.
The company’s process includes recovery and recycling of the Ra-226 target material and is intended to produce Ac-225 without the Ac-227 associated with direct high-energy proton irradiation of Th-232. IONETIX has continued adding cyclotron and production capacity, but public projections of future output should not be confused with verified current production or uncommitted material available for immediate purchase.
BWXT Medical produces and processes high-purity, non-carrier-added Ac-225 through a supply chain involving TRIUMF in Vancouver. TRIUMF irradiates targets, while BWXT Medical processes the resulting material, supports clinical and future commercial supply, and has filed an FDA Drug Master File covering its Ac-225 active pharmaceutical ingredient.
On August 3, 2026, parent company BWX Technologies agreed to sell the medical business to Nordic Capital as part of a transaction valued at up to $800 million that also includes Kinectrics’ stable-isotope operations. Until that transaction closes, BWXT Medical remains the operating producer under BWX Technologies; after closing, the business will be controlled by the Nordic Capital-backed company, although Nordic Capital itself should not be described as an Ac-225 producer.
Eckert & Ziegler is developing GMP-compliant, cyclotron-based Ac-225 production through its collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences, commonly known as UJF. The partners announced increased production volumes in 2026, and Eckert & Ziegler says GMP-grade material is available for preclinical and clinical programs.
The company has signed supply agreements with Actinium Pharmaceuticals, GlyTherix, Full-Life Technologies, SK Biopharmaceuticals and other drug developers. Those agreements and the reported increase in production support its inclusion as an active supplier, although contract announcements do not reveal current shipment volumes, customer allocations or available uncommitted capacity.
Actineer, the joint venture between ITM Isotope Technologies Munich and Canadian Nuclear Laboratories, is producing Ac-225 at Chalk River Laboratories in Canada. Its accelerator-based process uses Ra-226 targets, and the venture announced in July that it had demonstrated recovery and recycling of the target material.
ITM has entered agreements to supply Actineer-produced Ac-225 to radiopharmaceutical developers, including Alpha-9 Oncology. Public announcements support the conclusion that Actineer is producing material, but the company continues describing larger industrial-scale output as a capacity it is building toward rather than one it has already fully achieved.
NorthStar Medical Radioisotopes produces non-carrier-added Ac-225 from Ra-226 targets using electron-beam accelerators at its Beloit, Wisconsin, campus. The company began routine weekly production in the fourth quarter of 2025, has been scaling output during 2026 and reports having supplied Ac-225 to customers in more than 20 countries.
Isotope JSC publicly markets Ac-225 from Russian manufacturers associated with Rosatom. Russia has historically produced generator-derived Ac-225, but current public information does not provide enough detail about output, customer availability, specifications or the effects of geopolitical and trade restrictions to compare that supply directly with Western commercial sources.
Isotope JSC is primarily a commercial supplier and exporter rather than the facility physically producing the isotope. Russia should therefore be acknowledged in a global analysis without presenting Isotope JSC as another independent private producer equivalent to NorthStar, SpectronRx or Niowave.
The U.S. Department of Energy Isotope Program remains an important Ac-225 producer and distributor but is not a company. Its Tri-Lab effort combines capabilities at Brookhaven, Los Alamos and Oak Ridge national laboratories, producing accelerator-derived Ac-225 through the irradiation of Th-232 targets while also supplying generator-derived material recovered from Th-229.
The program reports routine availability and says accelerator-production batches are generally in the 50-to-100-millicurie range, with investments underway to increase batch sizes. Other government and research organizations, including the European Commission’s Joint Research Centre, also contribute material or production expertise but should be separated from private commercial suppliers.
A second group of companies is constructing facilities, commissioning equipment, developing production methods or signing agreements tied to future Ac-225 supply. These activities may produce meaningful capacity, but they are not equivalent to evidence that Ac-225 is currently being produced and released to customers.
Nusano expects to begin supplying Ac-225 in 2026 and has signed several agreements covering future production. Its June 2026 milestone confirmed successful particle acceleration at its Utah facility, but Nuclio Media did not identify a subsequent public announcement confirming an Ac-225 production batch or customer shipment.
Orano Med, SHINE Technologies, ASP Isotopes, NovAccel, Framatome and Actinium Pharmaceuticals are also developing or supporting future production capabilities. Hitachi and Tohoku University have demonstrated a 50-megabecquerel Ac-225 production batch, but that research achievement does not yet establish routine commercial supply.
These organizations should remain in a future-capacity category until public evidence establishes recurring production and release. A supply agreement alone may cover material expected years later and does not prove that a customer is receiving Ac-225 today.
The Ac-225 market cannot be understood by counting company names. TerraPower and Cardinal participate in the same supply chain, just as TRIUMF and BWXT Medical, UJF and Eckert & Ziegler, and Canadian Nuclear Laboratories and Actineer perform different roles within connected production systems.
The public record also does not permit an accurate ranking of the producers because companies have been reluctant to disclose current output, validated rather than theoretical capacity, committed customer allocations, available inventory, minimum orders, pricing or complete release specifications. Purity claims require similar caution because “high purity” does not necessarily represent a uniform standard across suppliers.
Drug developers may need to compare radionuclidic purity, Ac-227 content, metal impurities, specific activity, release testing, regulatory documentation and compatibility with a particular chelator or manufacturing process. Those differences help determine whether material from two suppliers is genuinely interchangeable for a specific drug program.
The existence of at least 10 corporate organizations involved in producing or releasing Ac-225 is evidence that the supply base is expanding, but it does not show that a new customer can call 10 suppliers, obtain comparable quotes and purchase interchangeable material. That remains the central problem in the Ac-225 market: the industry is becoming increasingly willing to say how much it expects to produce, but it remains reluctant to tell customers how much they can buy today.
